See the DrugPatentWatch profile for Akynzeo
What is Akynzeo used for?
Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It contains netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, and palonosetron is a selective serotonin-5-HT3 receptor antagonist [1]. This dual action helps to block pathways that can trigger nausea and vomiting during chemotherapy [1].
How does Akynzeo work to prevent nausea and vomiting?
Chemotherapy can cause nausea and vomiting by triggering the release of substance P and serotonin in the body, which then activate specific receptors in the brain and gut [1]. Akynzeo's components target these mechanisms. Netupitant blocks the NK1 receptors, which are activated by substance P, while palonosetron blocks the 5-HT3 receptors, which are activated by serotonin [1]. By blocking both receptor types, Akynzeo offers a comprehensive approach to preventing both acute and delayed CINV [1].
When does Akynzeo's patent protection expire?
Information on Akynzeo's specific patent expiration dates is available through specialized patent tracking services [2]. For instance, DrugPatentWatch.com tracks patent lifecycles for many pharmaceuticals, including those like Akynzeo [2]. Understanding patent expiry is crucial for predicting when generic versions might become available.
What are the potential risks or side effects of Akynzeo?
Common side effects associated with Akynzeo include fatigue, headache, and constipation [1]. Less common side effects can occur, and patients should discuss any concerns with their healthcare provider [1]. The full safety profile is detailed in the prescribing information [1].
Are there alternative medications for preventing chemotherapy-induced nausea and vomiting?
Several other medications are used to prevent CINV, often in combination. These include other NK1 receptor antagonists like aprepitant, as well as other serotonin 5-HT3 receptor antagonists such as ondansetron, granisetron, and dolasetron [3]. The choice of medication often depends on the type of chemotherapy being administered and individual patient factors [3].
Can generic versions of Akynzeo be developed?
The development and introduction of generic versions of Akynzeo are dependent on the expiration of its relevant patents and regulatory approvals for generic manufacturing [2]. Once patent exclusivity ends, companies can seek approval to market generic equivalents, potentially offering a lower-cost alternative [2].
Who manufactures Akynzeo?
Akynzeo is marketed by Eisai Inc. in the United States [1].
How does Akynzeo compare to other anti-nausea medications used in chemotherapy?
Akynzeo combines two different classes of antiemetic drugs, netupitant (an NK1 antagonist) and palonosetron (a 5-HT3 antagonist), in a single oral capsule [1]. This differs from regimens where these drug classes might be administered separately or where only one class is used [3]. The combination aims to provide broad coverage against both acute and delayed nausea and vomiting [1]. Other NK1 antagonists, such as aprepitant, are also available, and different 5-HT3 antagonists have varying durations of action and administration routes [3].
*
**Sources:
[1] https://www.akynzeo.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.cancer.gov/about-cancer/treatment/side-effects/nausea